Atria Investments Inc Decreases Stake in AbbVie Inc. $ABBV

Atria Investments Inc cut its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 6.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 167,508 shares of the company’s stock after selling 10,865 shares during the period. Atria Investments Inc’s holdings in AbbVie were worth $38,785,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Brighton Jones LLC grew its position in AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after buying an additional 3,401 shares during the period. Revolve Wealth Partners LLC boosted its stake in shares of AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after acquiring an additional 3,064 shares during the last quarter. Morningstar Investment Management LLC bought a new stake in shares of AbbVie during the 2nd quarter valued at $364,000. Brown Financial Advisory increased its stake in shares of AbbVie by 21.7% in the 2nd quarter. Brown Financial Advisory now owns 3,713 shares of the company’s stock worth $689,000 after purchasing an additional 662 shares in the last quarter. Finally, AEGON ASSET MANAGEMENT UK Plc raised its holdings in AbbVie by 0.8% in the 2nd quarter. AEGON ASSET MANAGEMENT UK Plc now owns 590,560 shares of the company’s stock worth $109,311,000 after purchasing an additional 4,794 shares during the period. 70.23% of the stock is currently owned by institutional investors.

AbbVie Stock Performance

ABBV stock opened at $220.74 on Thursday. The company’s fifty day moving average price is $223.47 and its 200-day moving average price is $220.29. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81. The company has a market capitalization of $390.12 billion, a PE ratio of 93.53, a price-to-earnings-growth ratio of 0.77 and a beta of 0.35.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. AbbVie’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, research analysts predict that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive: AbbVie’s real‑world PHASES migraine study could expand uptake for ubrogepant (an oral migraine treatment), improving its competitive positioning in migraine care and incremental revenue potential. AbbVie’s Real-World Migraine Study Could Quietly Boost Ubrogepant’s Market Potential
• Positive Sentiment: Positive: AbbVie updated its Phase 2 elezanumab study in acute cervical spinal cord injury — any favorable signals in neuroscience would bolster the pipeline and longer‑term growth optionality beyond immunology and aesthetics. AbbVie Updates Phase 2 Elezanumab Study in Acute Cervical Spinal Cord Injury: What Investors Should Watch
• Neutral Sentiment: Neutral: Analyst coverage is shifting — some upgrades/notes frame AbbVie as a stronger value/growth combination given Rinvoq and Skyrizi momentum, which supports the longer‑term revenue thesis but may be priced in. How Recent Analyst Shifts Are Reframing AbbVie (ABBV) And Its Valuation Story
• Neutral Sentiment: Neutral: Research/commentary expects 2026 top‑line growth from Rinvoq and Skyrizi (offsetting Humira erosion); these projections support consensus revenue targets but leave sensitivity to execution and pricing. Here’s What Will Drive AbbVie’s Top-line Growth in 2026
• Neutral Sentiment: Neutral: Coverage highlighting AbbVie as a value/attractive income stock (Zacks, Seeking Alpha mentions) can support demand from income‑oriented investors even as valuation debates continue. Here’s Why AbbVie (ABBV) is a Strong Value Stock
• Negative Sentiment: Negative: The big near‑term headwind is CMS selecting Botox for price negotiation under the Inflation Reduction Act; AbbVie filed suit against HHS challenging the move. If price controls are upheld, Botox revenue and pricing could be materially affected; the lawsuit increases regulatory uncertainty and likely pressured shares. AbbVie sues US health agency over Botox price controls
• Negative Sentiment: Negative: Reports that AbbVie is reshaping U.S. operations with Medicaid concessions and broader pricing/alignment moves (including commentary about large domestic manufacturing deals) suggest margin and access tradeoffs; these actions can depress near‑term profitability even if they support market access. AbbVie Reshapes U.S. Operations With Medicaid Concessions And Growth Focus

Analyst Ratings Changes

Several analysts have issued reports on ABBV shares. JPMorgan Chase & Co. boosted their price target on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a report on Monday, November 3rd. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a research report on Thursday, February 5th. Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. Piper Sandler restated an “overweight” rating and set a $289.00 target price (up previously from $284.00) on shares of AbbVie in a research note on Wednesday, November 5th. Finally, Scotiabank initiated coverage on shares of AbbVie in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and an average target price of $251.00.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.